An analysis of Lynch syndrome–associated ovarian cancer found that the malignancy tends to present at an early stage and has a generally good prognosis.
Women with endometrioid ovarian cancer present at a younger age and with earlier stage disease than those with serous ovarian cancer, according to a new analysis. The earlier presentation resulted in better 5- and 10-year overall survival rates as well.
The FDA granted accelerated approval to rucaparib (Rubraca), a PARP inhibitor, for the treatment of women with deleterious BRCA mutation-associated ovarian cancer.
A retrospective review showed that primary cytoreductive surgery was associated with longer survival than neoadjuvant chemotherapy in women with advanced-stage epithelial ovarian cancer.
Expression of mesothelium vascular cell adhesion molecule-1 (VCAM-1) is associated with poorer overall and progression-free survival in patients with epithelial ovarian cancer, according to a retrospective analysis.
The use of surveillance did not affect survival among women with stage I malignant ovarian germ cell tumors, according to a new retrospective analysis.
Adding the WEE1 inhibitor AZD1775 to carboplatin offered enhanced response rates in women with TP53-mutated ovarian cancer that was refractory or resistant to first-line platinum-based therapy in a phase II study.
Adding seribantumab to paclitaxel failed to improved progression-free survival in unselected patients with platinum-resistant or -refractory ovarian cancer. Expression of heregulin and HER2, however, could identify a subset of patients that derive benefit from the therapy.
The oral PARP inhibitor rucaparib showed strong activity and an acceptable safety profile in women with high-grade, BRCA-mutated ovarian carcinoma who had previously received at least two lines of chemotherapy.
The oral PARP inhibitor niraparib yielded significantly improved progression-free survival for women with platinum-sensitive, recurrent ovarian cancer in a phase III trial.